Science Highlights 2024: Head and Neck Cancer
This session highlights the most clinically relevant abstracts within the Head and Neck Cancer track of the 2024 ASTRO Annual Meeting scientific program. These noteworthy scientific abstracts share important findings and feature cutting-edge research from leaders in the field. The Discussant compares and contrasts the current data to help you digest the latest science; places the study into context; and describes how the study can be put into clinical practice, if recommended.
Highlighted abstracts include:
- Contralateral Neck Recurrence Rates in Head and Neck Carcinomas after Primary Surgery, Bilateral Neck Dissection, a Pathologically Negative Contralateral Neck, and Adjuvant Ipsilateral Neck Radiation
- Quality of Life (QOL) of Patients with Human Papillomavirus (HPV) associated Oropharyngeal Squamous Cell Carcinoma (OPSCC) in NRG-HN002
- HYHOPE: A Phase 1 Study of De-intensified Hypofractionated Radiation Therapy for Human Papillomavirus-associated Oropharynx Cancer
- HPV-Seq is Prognostic in p16-Positive Oropharyngeal Cancer (OPC): Independent Validation in a Large Prospective Cohort and a Secondary Analysis of NRG-HN002
- Global Interobserver Variations of Clinical Target Volume (CTV) Delineation among International Experts in Predefined Gross Tumor Volume (GTV) and Organs at Risk (OAR) Volumes in Head and Neck Cancer
- Acupuncture for (Chemo) Radiotherapy (CRT) - Related Dysphagia in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized Phase 2 Study
This activity is available from May 29, 2025 through 11:59 p.m. Eastern time on December 31, 2025.
This activity was originally presented and recorded at the 2024 ASTRO Annual Meeting.
Target Audience
The activity is designed to meet the interests of radiation oncologists, radiation oncology residents, physicists and radiation dosimetrists.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Gain knowledge of the use and technique of radiation therapy for head and neck cancers.
- Compare and contrast current data in head and neck cancer.
- Assess selected randomized and comparative trials in head and neck cancer.
Discussant: Michelle Mierzwa, MD
Michelle Mierzwa, MD, is employed by University of Michigan and serves as the Behavioral Health Committee Co-lead with the Michigan Radiation Oncology Quality Consortium.
The person(s) above served as the developer(s) of this activity. Additionally, the ASTRO Education Committee and the 2024 ASTRO Annual Meeting Education and Steering Committees had control over the content of this activity. All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Available Credit
- 0.50 AMA PRA Category 1 Credit™
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 0.50 Certificate of AttendanceThis activity was designated for 0.50 AMA PRA Category 1 Credit™.
Price
Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the free member rate.
- Nonmember: $79
- Member: Free
Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date.
Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.
The activity and its materials will only be available on the ASTRO website until December 31, 2025, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date.
Required Hardware/software
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.